Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform
Publish Date: 2026-06-25 05:00:00
Source Domain: www.businesswire.com
IRVINE, Calif.–(BUSINESS WIRE)–Johnson & Johnson today announced the commercial launch of the Dual Energy THERMOCOOL SMARTTOUCH SF (DE STSF) Platform in Europe, expanding physician access to a dual-energy catheter ablation solution designed for personalized care across workflows, anatomies and procedural strategies.i
The platform combines the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter, an irrigated contact-force sensing catheter, with the TRUPULSE Generator to enable delivery of both radiofrequency (RF) and pulsed field (PF) energy through a single catheter-based solution.i Designed to support precise and insight-driven ablation, the platform enables electrophysiologists to leverage both pulsed field and radiofrequency energy within the same procedure.i
Built on the THERMOCOOL SMARTTOUCH SF platform, a globally trusted catheter with extensive clinical validation and more than a million patients treated worldwide, DE STSF combines a familiar point-by-point workflow with the flexibility to tailor treatment approaches across a broad range of cardiac ablation procedures.i Leveraging the power of CARTO integration, ultra high-density mapping solutions and intracardiac ultrasound imaging, the platform delivers advanced electro-anatomical mapping, catheter visualization, contact-force feedback and PF/RF Index guidance. Together, these capabilities are designed to support procedural control and reproducible lesion creation.
“DE STSF is a welcome addition to the EP lab because it allows physicians to incorporate new technology based on the gold RF standard smarttouch SF platform while maintaining familiar workflows with greater versatility by seamlessly switching between RF and PFA,” said Nicolas Derval1, M.D., Bordeaux, France. “This flexibility also provides greater ability to adjust treatment to different patient anatomies, clinical needs and procedural goals while increasing safety in ablating the posterior wall for example.i”
“No two atrial…
